Effect of Statins on Liver Function Tests (LFTs) in Patients with Diabetes Presenting in CMH Rawalakot

Tayyiba Zia

doi:10.70749/ijbr.v3i5.1218

Authors

Tayyiba Zia Department of Medicine, CMH Rawalakot, Azad Kashmir, Pakistan.

DOI:

https://doi.org/10.70749/ijbr.v3i5.1218

Keywords:

Diabetes, Liver Function Tests, Statins

Abstract

Objectives: To find the effect of statin therapy on liver function tests in diabetic patients presenting at CMH Rawalakot. Study design: Qausi-experimental study. Place and duration of study: Department of Medicine, CMH, Rawalakot, from October 2024 to March 2025. Methodology: A total of 100 patients, aging between 40 to 70 years, diagnosed with type 2 diabetes since ≥1 year, and was not previously on statin therapy, were included in this study using consecutive sampling. All the demographics and related medical history was recorded. Baseline liver function tests (ALT, AST, ALP, GGT, and total bilirubin) and the blood glucose levels were recorded. Patients were recommended Rosuvastatin 20 mg/day for 3 months. The primary objectives of the study was to find the impact of statin therapy on liver function tests in diabetic patients presenting at our hospital. Values of Pre- and post-treatment LFT were compared using the paired t-test, with a p-value <0.05 taken as statistically significant. Results: The mean age in this study was 50.38±6.89 years (ranging from 36 to 64 years). The male gender was 58% of total study population while female gender was 42%. Comparison between baseline and post-treatment liver function test values after 3 months of statin therapy with Rosuvastatin 20 mg/day showed no statistically significant change in all the parameters of LFTS including ALT (p=0.14), AST (p=0.79), ALP (p=0.11), GGT (p=0.88) and total bilirubin levels (p= 0.17). The analysis of sub-group of patients with HbA1C levels ˃7% also showed no statistically significant change in LFTs. Conclusion: Statins are hepatically safe in diabetic patients, with no significant changes in liver function tests, supporting its clinical use for managing dyslipidemia in these patients.

Downloads

Download data is not yet available.

References

Gan, C., Yuan, Y., Shen, H., Gao, J., Kong, X., Che, Z., Guo, Y., Wang, H., Dong, E., & Xiao, J. (2025). Liver diseases: Epidemiology, causes, trends and predictions. Signal Transduction and Targeted Therapy, 10(1).

https://doi.org/10.1038/s41392-024-02072-z

Kakehashi, A., Suzuki, S., Ishii, N., Okuno, T., Kuwae, Y., Fujioka, M., Gi, M., Stefanov, V., & Wanibuchi, H. (2020). Accumulation of 8-hydroxydeoxyguanosine, L-arginine and glucose metabolites by liver tumor cells are the important characteristic features of metabolic syndrome and non-alcoholic steatohepatitis-associated Hepatocarcinogenesis. International Journal of Molecular Sciences, 21(20), 7746.

https://doi.org/10.3390/ijms21207746

Gao, E., Hercun, J., Heller, T., & Vilarinho, S. (2021). Undiagnosed liver diseases. Translational Gastroenterology and Hepatology, 6, 28-28.

https://doi.org/10.21037/tgh.2020.04.04

Hossain, M. J., Al‐Mamun, M., & Islam, M. R. (2024). Diabetes mellitus, the fastest growing global public health concern: Early detection should be focused. Health Science Reports, 7(3).

https://doi.org/10.1002/hsr2.2004

Nogueira, J. P., & Cusi, K. (2024). Role of insulin resistance in the development of nonalcoholic fatty liver disease in people with type 2 diabetes: From bench to patient care. Diabetes Spectrum, 37(1), 20-28.

https://doi.org/10.2337/dsi23-0013

Jung, I., Koo, D., & Lee, W. (2024). Insulin resistance, non-alcoholic fatty liver disease and type 2 diabetes mellitus: Clinical and experimental perspective. Diabetes & Metabolism Journal, 48(3), 327-339.

https://doi.org/10.4093/dmj.2023.0350

Feingold KR. Dyslipidemia in Patients with Diabetes. [Updated 2023 Dec 4]. In: Feingold KR, Ahmed SF, Anawalt B, et al., editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000-

https://www.ncbi.nlm.nih.gov/books/NBK305900/

Thompson, P. D., Panza, G., Zaleski, A., & Taylor, B. (2016). Statin-Associated side effects. Journal of the American College of Cardiology, 67(20), 2395–2410.

https://doi.org/10.1016/j.jacc.2016.02.071

Newman, C. B., Preiss, D., Tobert, J. A., Jacobson, T. A., Page, R. L., Goldstein, L. B., Chin, C., Tannock, L. R., Miller, M., Raghuveer, G., Duell, P. B., Brinton, E. A., Pollak, A., Braun, L. T., & Welty, F. K. (2019). Statin safety and associated adverse events: A scientific statement from the American Heart Association. Arteriosclerosis, Thrombosis, and Vascular Biology, 39(2).

https://doi.org/10.1161/atv.0000000000000073

Warden, B. A., Guyton, J. R., Kovacs, A. C., Durham, J. A., Jones, L. K., Dixon, D. L., Jacobson, T. A., & Duell, P. B. (2023). Assessment and management of statin-associated muscle symptoms (SAMS): A clinical perspective from the national lipid association. Journal of Clinical Lipidology, 17(1), 19-39.

https://doi.org/10.1016/j.jacl.2022.09.001

Ashraf, J., Ali Khan, M., Minhaj, S., Khatti, S., Aarij, K. M., Shehzad, Dr. M., & Khan, T. M. (2020). Statins and Abnormal Liver Function Tests: Is There a Correlation? Cureus, 12(8).

https://doi.org/10.7759/cureus.10145

Ather, M. M., Rasheeq, T., Ahmed, M., & Furqan, A. (2019). Type II diabetes mellitus;. The Professional Medical Journal, 26(04).

https://doi.org/10.29309/tpmj/2019.26.04.3356

Nascimbeni, F., Aron-Wisnewsky, J., Pais, R., Tordjman, J., Poitou, C., Charlotte, F., Bedossa, P., Poynard, T., Clément, K., & Ratziu, V. (2016). Statins, antidiabetic medications and liver histology in patients with diabetes with non-alcoholic fatty liver disease. BMJ Open Gastroenterology, 3(1), e000075.

https://doi.org/10.1136/bmjgast-2015-000075

Rusu, E., Jinga, M., Rusu, F., Ciurtin, C., Enache, G., Dragomir, A., ... & Radulian, G. (2013). Statin therapy in patients with diabetes and hepatitis C. Farmacia, 61(6), 1204-1215.

https://discovery.ucl.ac.uk/id/eprint/10131652/

Bril, F., Portillo Sanchez, P., Lomonaco, R., Orsak, B., Hecht, J., Tio, F., & Cusi, K. (2017). Liver safety of statins in prediabetes or T2DM and nonalcoholic Steatohepatitis: Post hoc analysis of a randomized trial. The Journal of Clinical Endocrinology & Metabolism, 102(8), 2950-2961.

https://doi.org/10.1210/jc.2017-00867

Ho, A., Kiener, T., Nguyen, Q.-N., & Le, Q. A. (2024). Effect of Statin Use on Liver Enzymes and Lipid Profile in Patients with Non-Alcoholic Fatty Liver Disease (NAFLD). Journal of Clinical Lipidology, 18(4).

https://doi.org/10.1016/j.jacl.2024.03.003

Rajabian, M., Nejad, E. H., & Moghaddam, H. T. (2018). Comparison of Elevated Liver Enzymes in Type 2 Diabetic Patients in User and Non-User of Statin. DOAJ (DOAJ: Directory of Open Access Journals), 6(12).

https://doi.org/10.22038/ijp.2018.34136.3015

Cheon, D. Y., & Jo, S.-H. (2022). Adverse effects of statin therapy and their treatment. Cardiovascular Prevention and Pharmacotherapy, 4(1), 1–6.

https://doi.org/10.36011/cpp.2022.4.e4